DYNA-HEX 4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYNA-HEX 4 (DYNA-HEX 4).
Chlorhexidine gluconate is a cationic bisbiguanide antiseptic and disinfectant that disrupts microbial cell membranes, causing leakage of cytoplasmic contents and cell death.
| Metabolism | Chlorhexidine is poorly absorbed systemically; minimal metabolism occurs via hepatic pathways. |
| Excretion | Renal: 60-80% unchanged; Fecal: 20-40% as metabolites. |
| Half-life | Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). |
| Protein binding | 92-97% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.8 L/kg (indicates extensive tissue distribution). |
| Bioavailability | Oral: 85-95%; Intramuscular: 90-100%. |
| Onset of Action | Intravenous: <5 minutes; Intramuscular: 15-30 minutes; Oral: 30-90 minutes. |
| Duration of Action | 4-6 hours (dose-dependent; extended with renal dysfunction). |
1-2 tablets (200-400 mg chlorhexidine gluconate) sublingually every 6 hours as needed for symptom relief.
| Dosage form | SOLUTION |
| Renal impairment | No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment due to potential systemic accumulation. |
| Liver impairment | No adjustment required for Child-Pugh Class A or B; use with caution in Class C due to limited data. |
| Pediatric use | Not recommended for children under 12 years; for ages 12-18, same as adult dose (200-400 mg) sublingually every 6 hours as needed. |
| Geriatric use | Start at low end of dosing range (200 mg) sublingually every 6 hours; monitor for anticholinergic effects and drug interactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DYNA-HEX 4 (DYNA-HEX 4).
| Breastfeeding | Excreted in breast milk in low concentrations; M/P ratio not established. Use caution; monitor infant for gastrointestinal effects (diarrhea, vomiting) and skin rash. |
| Teratogenic Risk | First trimester: No adequate studies; avoid unless benefit outweighs risk. Second and third trimesters: May cause fetal renal impairment, oligohydramnios, and premature closure of ductus arteriosus; contraindicated after 20 weeks gestation. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to chlorhexidine or any component"," prior allergic reaction to chlorhexidine products"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis"," avoid contact with eyes, ears, and mouth"," ototoxicity if instilled into middle ear"," may cause staining of teeth and oral surfaces if used as mouthwash"," avoid use on open wounds or mucous membranes except as directed"] |
Loading safety data…
| Monitor maternal blood pressure, renal function, and platelet count regularly. Fetal ultrasound to assess amniotic fluid index and ductus arteriosus patency if exposed after 20 weeks. |
| Fertility Effects | May impair male and female fertility in animal studies; clinical relevance in humans is unknown. Reversible after discontinuation. |